MALAT1-regulated gene expression profiling in lung cancer cell lines

Area of Science:

• Molecular Oncology
• Biomarker Discovery
• Cancer Genomics

Background:

• Non-small cell lung cancer (NSCLC) presents a significant clinical challenge due to its poor prognosis.
• Identifying molecular biomarkers is crucial for early NSCLC diagnosis, treatment, and improved patient outcomes.
• Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is implicated in NSCLC progression and proposed as a diagnostic/prognostic marker.

Purpose of the Study:

• To profile gene expression changes regulated by MALAT1 in NSCLC cell lines.
• To investigate the correlation between MALAT1 and differentially expressed genes (DEGs) using bioinformatics.
• To identify potential biomarkers for NSCLC diagnosis and prognosis.

Main Methods:

• Quantitative reverse transcription PCR (RT-qPCR) for MALAT1 expression.
• Functional assays (cell counting, colony formation, wound healing, Transwell invasion) to assess MALAT1's role.
• RNA sequencing (RNA-seq) for transcriptome profiling upon MALAT1 knockdown.
• Gene Ontology (GO) and KEGG pathway analyses for DEG enrichment.
• Bioinformatic database analysis (OncoLnc, TNMplot) for survival and expression correlation.

Main Results:

• MALAT1 expression was significantly elevated in NSCLC cell lines compared to normal lung cells.
• MALAT1 knockdown inhibited NSCLC cell survival, proliferation, migration, and invasion.
• RNA-seq identified 198 upregulated and 266 downregulated DEGs upon MALAT1 knockdown.
• Five common DEGs (PGAM1, PGAM4, NOL6, NAP1L5, SESN1) were selected based on survival analysis and validated.
• Gene expression levels of these five DEGs correlated with NSCLC patient survival.

Conclusions:

• MALAT1 acts as an oncogene, promoting NSCLC cell proliferation, survival, and invasion.
• Five DEGs (PGAM1, PGAM4, NOL6, NAP1L5, SESN1) are closely associated with NSCLC tumorigenesis and patient survival.
• These identified DEGs warrant further investigation as potential therapeutic targets and prognostic biomarkers for NSCLC.